Publication of Treatment Compass

To help improve the care of patients with Long COVID, the expert group on Long COVID Off-Label Use, which is located at the Federal Institute of Drugs and Medical Devices (BfArM), developed a Treatment Compass that provides an overview of appropriate substances and substance groups. In particular, the Compass provides treatment recommendations regarding the use of medicinal products in their approved indications to treat symptoms associated with Long COVID. That means, these prescription-only medicinal products can be prescribed and used ‘on-label’ in the indications for which they are approved. However, this experience-based Treatment Compass is not a substitute for evidence-based off-label use recommendations regarding the specific treatment of Long COVID. The evaluation of scientific evidence on the off-label use of medicinal products remains one of the central tasks of the Expert Group on Long COVID Off-Label Use.